Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.

Archie Bleyer, Kaukab M Rajput, Vassilios Papadakis, Allison F O'Neill, Franciscus A Diepstraten, Annelot J M Meijer, Gareth J Veal, Marry M van den Heuvel-Eibrink, James I Geller, Rudolf Maibach, Eric Bouffet, Michael Sullivan, Alwin D R Huitema, Penelope R Brock, Brice Fresneau, Per Kogner, Marc Ansari

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024;42(18):2219-2232

PMID: 38648563

Free Full Text on PubMed Central View on PubMed

Abstract

PURPOSE

Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL).

DESIGN

A comprehensive narrative review is presented.

RESULTS

Thirty-one articles were summarized. Overall, systemic STS effectively reduces CIHL in the preclinical and controlled clinical study settings, in both adults and children with cancer. The extent of CIHL reduction depends on the timing and dosing of STS in relation to cisplatin. Both preclinical and clinical data suggest that systemic STS may affect plasma platinum levels, but studies are inconclusive. Delayed systemic administration of STS, at 6 hours after the cisplatin infusion, does not affect cisplatin-induced inhibition of tumor growth or cellular cytotoxicity in the preclinical setting, nor affect cisplatin efficacy and survival in children with localized disease in the clinical setting.

CONCLUSION

Systemic administration of STS effectively reduces the development and degree of CIHL in both the preclinical and clinical settings. More studies are needed on the PK of STS and cisplatin drug combinations, the efficacy and safety of STS in patients with disseminated disease, and the ability of STS to prevent further deterioration of pre-established hearing loss.

Address: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland.; Division of Pediatric Neuro-Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Radiation Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, Canada.; Department of Children and Adolescents Oncology, Gustave Roussy, University Paris Saclay and Radiation Epidemiology Team, CESO, Inserm U1018, Villejuif, France.; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Pediatric Oncology and Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden.; ETOP IBCSG Partners Foundation, Bern, Switzerland.; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.; Department of Pediatric Hematology-Oncology (TAO), Agia Sofia Children's Hospital, Athens, Greece.; Department of Pediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; Children's Cancer Centre and Department of Pediatric Oncology, Royal Children's Hospital, Melbourne, Victoria, Australia.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Wilhelmina Childrens' Hospital, Division of Child Health, Utrecht, the Netherlands.; Department of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.

DOI: 10.1200/JCO.23.02353

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/cancerinchildren.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Thiosulfates, Neoplasms, Cisplatin, Antineoplastic Agents, Hearing Loss, Child